Three key insights emerge from the latest comprehensive analysis of coffee and cancer risk. First, a pooled analysis involving 1.5 million women demonstrated a 20% lower endometrial cancer risk associated with consuming four cups of coffee daily, establishing a measurable dose-response relationship. Second, the protective compounds in coffee are polyphenols and chlorogenic acid rather than caffeine—patients concerned about caffeine intake can obtain equivalent protective benefits from decaffeinated coffee. Third, clinical validation is advancing: a Phase 1/2 trial at Massachusetts General Hospital will begin testing whether these associations reflect causation in colorectal cancer patients, with results expected in 2027 and beyond. These findings suggest moderate-strength evidence supporting coffee consumption as a potential dietary strategy for cancer risk reduction, though individuals should consult healthcare providers regarding personal dietary choices.
Was this article helpful?
